Challenges and Risks in Development and Manufacture of COVID-19 Vaccine
Posted on October 26, 2020
Rajesh K. Gupta, President and Principal Consultant Seema Parveen, Formerly Post-doctorate Research Scientist Pushker Raj, Chief of Immunology and Virology Unit
Biologics Quality & Regulatory Consultants, LLC
Food & Drug Administration, Center for Biologics Evaluation & Research, Kensington, MD
District of Columbia Department of Forensic Sciences Public Health Laboratory Division, Washington, DC 20024
Abstract Don’t Ignore Challenges and Risks, Face them and Manage/Mitigate them. As the COVID-19 pandemic continues, there has been an optimism of achieving herd immunity against the disease. Herd immunity through infection or vaccination of most of the population seems to be the key in controlling...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
